Fertility
Eight in ten Brits consider stopping IVF treatment due to costs, research reveals
The study found that two thirds of people in the UK expect their employer to cover IVF

Brits are struggling to cope with the costs of IVF and expect more support from their employers, a new study has shown.
The virtual fertility clinic Apricity conducted a survey of 500 people in the UK who are either undergoing fertility treatment (40 per cent) or preparing for fertility treatments (60 per cent).
It found that 84 per cent of the patients surveyed funded their treatment themselves, with the NHS covering only about 20 per cent of treatments.
One cycle of IVF with medication costs upwards of £7,000 and at least three cycles are recommended for success.
This put huge financial pressure on patients who struggled to pay for their treatment, despite the average income of respondents was £31,400.
The waiting time is between one and two years in England, and whether you are able to access NHS fertility treatment depends on your GP’s postcode, with different regions offering different levels of access to NHS IVF and some offering none at all.
Women can be eligible for three rounds of NHS-funded IVF treatment if they have been trying unsuccessfully to start a family for two or more years, or if they have had 12 or more unsuccessful rounds of artificial insemination.
Approximately 81 per cent of participants surveyed by Apricity considered giving up treatment while 39 per cent only went through two of the three cycles needed for full treatment due to financial pressure.
The study also showed that 57 per cent of patients did not understand the true financial costs at stake before starting treatment.
Almost two thirds said they would expect their employer to cover these costs, either in full or part, and 82 per cent said they would only consider working for an employer that offered fertility benefits if they were looking to do IVF again.
Fertility treatment is a significant time commitment, which can take up months of a patient’s life.
While 84 per cent of respondents had to take time off during treatment, more than a third (38 per cent) took this time off under annual leave and a further 16 per cent took no time off at all.
Additionally, 62 per cent of UK responders found fertility treatment just as, if not more stressful than losing their job, with half of them finding it just as if not more stressful than the bereavement of a close loved one.
“With the private sector taking up the vast majority of the UK fertility market and the NHS under massive strain, more people are looking to their employers to step up and support them on their fertility journey both financially and with flexible working,” said Caroline Noublanche, founder and CEO of Apricity.
“This is currently much more common in the US, where 81 per cent of the best workplaces are providing reimbursement for fertility treatments compared to just 17 per cent already in place in the UK.
“At Apricity we’re working to make the fertility journey as smooth and stress-free as possible, and have already partnered with some of the largest UK employers, insurers and employee benefit platforms including Axa PPP, Reward Gateway and Mercer Marsh, and we expect more to join us offering fertility benefits.
“We try to remove a lot of the disruption for patients and employers alike by significantly reducing the number of visits to the clinic.”
She added: “If more employers supported the process and more clinics used new technology solutions, we’d be able to collectively better manage the process and reduce the stigma.”
The study also found that fertility treatment is likely to have negative consequences for both romantic and personal relationships, with 80 per cent of couples saying it caused friction in their relationship.
Half of respondents chose no to tell friends/family about their IVF treatments, with shame and embarrassment cited as the main reason.
Fertility
Infertility may be risk factor for early menopause, study suggests
Fertility
AI patch could detect hidden hormone disruptions behind unexplained infertility

Even when standard clinical tests show normal hormone levels, men and women may have hidden problems in how their reproductive hormones are timed and coordinated, potentially affecting fertility, new research suggests.
The findings suggest reproductive health may depend not only on hormone levels in the bloodstream but also on the rhythm, timing and synchronisation of hormone changes across hours, days and the menstrual cycle.
Researchers said a wearable skin sensor patch, combined with artificial intelligence, could help detect endocrine dysfunction earlier and support more personalised fertility care.
Unexplained infertility affects about 15 to 30 per cent of couples and is diagnosed when standard investigations reveal no clear cause.
In men, current tests for infertility or hypogonadism, defined clinically as low testosterone, often include a single morning serum testosterone measurement.
In women, fertility assessment typically examines menstrual cycle characteristics and reproductive hormones such as luteinising hormone, follicle-stimulating hormone, oestradiol and progesterone.
However, reproductive hormones are not static markers. They are dynamic biological signals that rise and fall in regulated patterns throughout the day and across the menstrual cycle.
Testosterone, for example, follows a diurnal rhythm, meaning it changes across the day, while female reproductive hormones act through coordinated feedback loops involving the hypothalamic, pituitary and ovarian systems.
A single blood test may therefore miss clinically important disruption in hormonal timing.
In one study, Dr Tinatin Kutchukhidze, from the University of Oxford, examined 102 men in Georgia and the UK.
The participants were aged 22 to 38 and had normal morning total testosterone levels, measured at 12 to 35 nanomoles per litre, with or without infertility or symptoms of hypogonadism.
Hypogonadism is a condition in which the body produces too little testosterone or other sex hormones.
Kutchukhidze and colleagues used wearable AI-enabled skin sensor patches to measure testosterone levels every 15 minutes across four days.
The team found that men with symptoms had significantly disrupted testosterone rhythms, despite standard laboratory tests showing normal testosterone levels.
These previously undetected rhythm abnormalities were also associated with reduced sperm concentration and symptoms of androgen deficiency.
Androgens are hormones, including testosterone, that play an important role in reproductive health.
Kutchukhidze said: “For the first time, we have been able to track androgen patterns in real time across several days with a novel, non-invasive, continuous, AI-driven testosterone monitoring patch, compatible with Android and iPhone mobile devices.
“Previous research suggests that a normal morning testosterone level is sufficient to exclude clinically significant androgen deficiency. However, our findings challenge that assumption by demonstrating that men with normal serum testosterone may still exhibit marked disturbances in hormonal rhythmicity associated with reproductive dysfunction.”
According to the abstract, the study compared 54 men with infertility or hypogonadal symptoms with 48 age-matched healthy controls.
Mean morning serum testosterone did not differ significantly between symptomatic men and controls, at 22.4 ± 3.1 compared with 23.1 ± 3.5 nanomoles per litre.
Continuous AI-assisted monitoring, however, revealed significant differences in androgen dynamics.
Men with symptoms had lower diurnal amplitude than controls, at 5.2 ± 1.1 compared with 8.7 ± 1.4 nanomoles per litre.
The AI-derived rhythm indices predicted subclinical dysfunction with an area under the curve of 0.87, compared with 0.61 for static serum testosterone testing.
In diagnostic research, the area under the curve is used to assess how well a test distinguishes between groups, with higher values indicating stronger discrimination.
A second study by Kutchukhidze’s team examined female reproductive hormone rhythms.
The researchers developed an AI-driven metric called Endocrine Rhythm Integrity to assess whether reproductive hormones were changing in the correct pattern, at the correct time and in the correct relationship to one another across the menstrual cycle.
Endocrine refers to the hormone system, while endocrine dysfunction means hormones are not being produced or regulated in a typical way.
The team analysed data from 312 women aged 18 to 22 who had self-reported regular menstrual cycles.
Participants included fertile controls and women with unexplained infertility.
The researchers assessed key reproductive hormones during the luteal phase, including luteinising hormone, follicle-stimulating hormone, oestradiol and progesterone.
The luteal phase is the part of the menstrual cycle after ovulation. Ovulation is the release of an egg from the ovary.
They also incorporated physiological data such as basal body temperature, heart rate and sleep patterns.
Basal body temperature is the body’s resting temperature and can shift slightly around ovulation.
The study found that women with unexplained infertility had lower Endocrine Rhythm Integrity scores even when conventional hormone levels appeared normal.
Lower scores predicted infertility and were also associated with a higher incidence of implantation failure, when an embryo does not successfully attach to the womb lining.
Kutchukhidze said: “Our study reveals that a woman may have a seemingly healthy menstrual cycle and normal hormone levels but still experience hidden endocrine dysfunction that affects her ability to conceive.
“Rather than analysing hormone levels as isolated values, Endocrine Rhythm Integrity evaluates whether reproductive hormones are changing in the correct pattern, at the correct time and in the correct relationship to one another across the menstrual cycle.”
In the female study, mean cycle length did not differ significantly between fertile and infertile groups, at 28.9 ± 2.3 compared with 28.9 ± 2.5 days.
Endocrine Rhythm Integrity scores, however, were lower in the infertility group, at 0.61 ± 0.12 compared with 0.78 ± 0.10.
Disrupted endocrine rhythm integrity was observed in 64 per cent of infertile participants despite hormonally normal mid-luteal progesterone levels.
The metric independently predicted infertility status after adjustment for age, body mass index and anti-Müllerian hormone.
Anti-Müllerian hormone is made by reproductive tissues and is best known as a marker of ovarian reserve, meaning an estimate of the number of eggs remaining in the ovaries.
Receiver operating characteristic analysis indicated that Endocrine Rhythm Integrity identified infertility more effectively than cycle length or single-time-point progesterone assessment.
Lower Endocrine Rhythm Integrity scores were also associated with a higher incidence of implantation failure.
Kutchukhidze said: “Our AI-driven rhythm analyses were significantly better at identifying subclinical reproductive dysfunction than conventional testing, suggesting that both female and male endocrine disorders may not simply be disorders of hormone quantity, but rather disorders of hormonal timing, synchronisation and biological rhythm.”
The team will next assess whether the tool can reliably predict fertility outcomes across different reproductive conditions in larger and more diverse populations.
Fertility
Gum disease may impair female fertility and egg quality – study
Menopause1 week agoPerimenopause misinformation ‘putting women at risk’
Insight4 weeks agoNIH Grant terminations disproportionately impact minority scientists, research finds
Adolescent health4 weeks agoWUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty
Insight3 weeks agoPCOS renamed after decade-long campaign to end ‘cyst’ misconception
Hormonal health2 weeks agoNHS urged to update website following renaming of PCOS
Menopause4 weeks agoCBT shows promise for menopause insomnia and hot flashes
Entrepreneur1 week agoWomen’s Health Innovation Summit opens submissions for 2026 Innovation Showcase
News1 week agoThree menopause innovators shortlisted for Femtech World Award














4 Comments